Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDAC Member Resigns Over Plan B, Rallies Fellow Panelists To Action

This article was originally published in The Pink Sheet Daily

Executive Summary

Former panel member and consultant says he will pursue options such as organizing a group letter to a medical journal from advisory committee members protesting FDA’s postponement of the Plan B decision.

You may also be interested in...

FDA Women’s Health Director Resigns Over Plan B

Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”

FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts